This trial is evaluating whether TULSA-PRO will improve 1 primary outcome and 5 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 3, 6, 12, 18, 24, and 36 months.
This trial requires 15 total participants across 2 different treatment groups
This trial involves 2 different treatments. TULSA-PRO is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Patients with late-stage, advanced prostate cancer have a very poor prognosis. With current treatment, no cure is possible, but treatment reduces symptoms and improves quality of life. Treatment should be considered for patients with asymptomatic, early-stage disease.
Prostate cancer is a cancer that forms in the prostate and typically appears in men over the age of 50. It is often identified by frequent, painful or bloody urination or painful ejaculation. PSA-based screening is considered reasonable for all men over 50 years of age, as the American College of Physicians/US Preventive Services Task Force. The use of age-based PSA screening remains controversial but may increase detection rates of asymptomatic disease and decrease mortality and morbidity from prostate cancer.
We hypothesise that certain signs could be related to [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). These signs, mainly related to high-grade cancers, will be discussed. The clinical signs are not conclusive to the diagnosis of prostate cancer, but they should be considered in the clinical evaluation of the patient.
Treatment for prostate cancer is highly variable and depends on the severity, grade, stage and extent of the condition. Common options include surgery or radiation therapy. If radiation therapy is used it is typically provided by a radiobiologist specialist.
There appears to be three main types of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) based on where they start: on the skin or lining of the urinary tract, at the opening of the body-prostate-skin junction, and inside the outer prostate. The number of genes that have been shown to be affected by prostate cancer varies depending on which form of the cancer is present, but the same genes probably cause prostate cancer in all forms of the disease. Most cancers that are detected at the start of the disease, and are potentially curable, are from early prostate cancer that has not spread inside healthy tissues. Prostate cancer is usually diagnosed by screening and by examining the blood in samples taken from the prostate by using a PSA level above 10 ng/mL.
Approximately 10.1 million men were diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in 2006 in the United States. In 2006, 1.7 million men were newly diagnosed with prostate cancer and 2 million men were diagnosed with a localized prostate cancer recurrence. For most men diagnosed with prostate cancer, prostate specific antigen testing or biopsy was performed.
The data suggest the existence of a general belief that Tulsa-related practices are able to prevent many forms of illnesses, as well as treatments for such and a range of other conditions. While there may be a tendency to believe that the Tulusa Clinic is 'all about prostate cancer' it may not be entirely clear whether this has not been a consequence to the lack of clinical research. It is likely that both the belief and the practice are in fact a balance between religion and scientific medical thinking.
Even in the presence of a prostate specific antigen (PSA) >4 ng/mL, age-specific rates of developing prostate cancer are rare. Thus, in the absence of other risk factors for prostate cancer in men without a prior diagnosis, PSA levels alone should not be used for counseling about the incidence of prostate cancer or for establishing an acceptable surveillance program. answer: Men without a prior diagnosis of prostate cancer may be considered for PSA only-based screening, but in these men, even men with a 4+ PSA result, prostate cancer has a prevalence that is only 10%, less than what would be expected from age-related rates alone.
The current technology for detection of early lesions has a fairly high sensitivity and specificity. The use of biochemical techniques alone may accurately identify patients who would receive a favorable treatment.
The data indicate that Tulsa is an effective and safe treatment of advanced prostate cancer. Results from a recent paper show that Tulsa is superior to the placebo in its effectiveness, tolerability, and safety profile. Results from a recent paper demonstrates Tulsa to be a highly active alternative therapy for advanced prostate cancer with a relatively benign risk/benefit ratio.
Results from a recent clinical trial of this study suggest that TPS is primarily used in combination with other treatments rather than as a single treatment. However, the use of combination treatment as opposed to monotherapy treatment should be studied further.